We have recently identified a novel signaling pathway downstream of the PASK protein kinase, which connects signaling cues to phosphorylation of Wdr5, a member of MLL, SET1 and other histone-modifying enzymatic complexes, to drive transcriptional activation of Myog and myogenesis (Kikani et al., 2016) . Our data show that PASK, via Wdr5 phosphorylation, collaborates with MyoD for transcriptional activation of Myog to drive the myogenesis program (Kikani et al., 2016) . In response to differentiation cues, PASK phosphorylates Wdr5 at Ser49, which leads to enhanced MyoD recruitment and activation of the Myog promoter. Thus, we hypothesized that PASK-Wdr5 are intermediates of the signaling pathways that drive myogenesis (Kikani et al., 2016) .
However, it remained unclear how differentiation signaling cues might activate the PASK-Wdr5 pathway. Here, we identify PASK as an interacting partner and substrate of mTORC1 that is a necessary mediator of its myogenic function. Our data suggest that mTORC1 connects niche-derived nutrient sufficiency and hormonal signals to epigenetic complexes such as MLL via PASK phosphorylation to drive MuSCs differentiation.
Results

Nutrients and insulin activate PASK in an mTORC1-dependent manner
We have previously reported that PASK expression was induced several-fold upon skeletal muscle injury and that loss of PASK resulted in severe defects in muscle regeneration (Kikani et al., 2016) . We showed that PASK activity was also posttranslationally stimulated during in vitro myogenesis (Kikani et al., 2016) . To understand if this activation of PASK is part of its pro-myogenic function, we first asked if PASK is similarly activated during muscle regeneration in vivo. To do so, we generated mice expressing V5-tagged human PASK (hPASK) from the Rosa26 locus (termed Rosa26 hPASK-V5 ). Parenthetically, probably due to its post-translational regulation, over-expression of human PASK in mice did not result in any overt skeletal muscle phenotype in uninjured animals. However, during regeneration, Rosa26 hPASK-V5 mice showed a modest elevation of Myog mRNA and the MyoG target myosin heavy chain (Myh3) ( Figure S1A ) consistent with the known function of PASK to enhance myogenic gene expression. Consistent with the enhanced regenerative program in mice with PASK overexpression, MuSCs derived from the Rosa26 hPASK-V5 mice showed morphological evidence of differentiation as early as one day after isolation in culture media whereas wild-type MuSCs remained mononucleated for up to two days ( Figure S1B ). Using this PASK allele, which is not subject to transcriptional regulation ( Figure S1A , compare hPASK vs. mPASK mRNA levels), we measured PASK kinase activity during tibialis anterior (TA) muscle regeneration. As shown in Figure 1A , PASK activity, as assessed by autophosphorylation (Kikani et al., 2010; Kikani et al., 2016) , was induced 3 days after injury. The increase in PASK activity coincided with the time point when both MyoG and endogenous mouse PASK expression is induced ( Figure 1A , Figure S1A ).
To understand how niche signals, like nutrients and insulin, activate PASK during muscle regeneration, we examined PASK activation by these stimuli in a cell-autonomous manner. As shown in Figure 1B , PASK was acutely and transiently activated by insulin stimulation in CHO-K1 cells. Similarly, glucose and amino acids such as L-leucine, which are enriched in the stem cell niche, also activate PASK in HEK293E cells ( Figure 1C ).
While glucose activated PASK modestly but consistently, we observed a strong increase in PASK activity upon addition of L-leucine to cell culture media ( Figure 1C ). Since mTOR complex 1 (mTORC1) is a convergence point in both insulin and amino acid signaling (Saxton and Sabatini, 2017) , we asked if the mTORC1 activity is required for PASK activation. As shown in Figure 1C , the addition of the mTORC1 inhibitor rapamycin (Yip et al., 2010) completely blocked PASK activation by glucose and Lleucine.
To further explore the role of mTORC1 in the regulation of PASK activity downstream of nutrient and insulin stimulation, we analyzed PASK activity in the presence or absence of kinase modulators that either augment or inhibit mTORC1 activity. AMP-activated protein kinase (AMPK) is a negative regulator of mTORC1 kinase function (Inoki et al., 2012) . As shown in Figure 1D -E, insulin and high glucose synergistically activated PASK, and this was suppressed by pretreatment with the AMPK activator 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) to an extent similar to rapamycin treatment. AMPK phosphorylates and activates Tsc2, which negatively regulates mTORC1 function (Inoki et al., 2003b) . Consistent with that, Tsc2 -/-mouse embryonic fibroblasts (MEFs), complemented with empty vector control but not with human Tsc2 (Onda et al., 1999) , showed mTORC1 hyperactivation as evidenced by increased phosphorylation of the mTORC1 substrate p70S6K ( Figure 1F ). Loss of Tsc2 also increased PASK kinase activity as shown by increased in vitro autophosphorylation and phosphorylation of its heterologous substrate Ugp1 ( Figure 1F ) (Smith and Rutter, 2007) . Tsc2 functions as a GTPase-activating protein (GAP) for the Rheb GTPase, which stimulates mTORC1 activity (Inoki et al., 2003a) . Expression of a constitutively activated Rheb (Rheb Q64L ), which hyperactivates mTORC1, also resulted in increased PASK activity ( Figure 1G ). On the other hand, silencing mTOR resulted in a near complete block of insulin-stimulated PASK activation ( Figure 1H ).
Finally, to test whether mTORC1 contributes to PASK activation in muscle stem cells, we isolated MuSCs from Rosa26 hPASK-V5 mice and assessed PASK activation by insulin after silencing Tsc2. Not surprisingly based on our previous results from injury experiments, PASK was activated during MuSC isolation but was further activated by insulin stimulation (Figure 1I , J). The loss of Tsc2 resulted in PASK activation both in the presence or absence of insulin. Thus, our results demonstrate that the mTORC1 complex activates PASK in response to insulin and nutrient signaling.
PASK is phosphorylated by mTORC1 at multiple residues to stimulate its activity.
We hypothesized that mTORC1-dependent phosphorylation of one or more residues on PASK might result in its activation by nutrients and insulin. Therefore, we performed metabolic in-cell labeling using radioactive ( 32 P) phosphate in Tsc2 -/-, or hTsc2
complemented Tsc2 -/-MEFs in the presence or absence of rapamycin. As shown in Figure   2A , endogenous PASK derived from Tsc2 -/-MEFs showed significantly increased phosphorylation compared with hTsc2-complemented cells. Furthermore, this increase in PASK phosphorylation was partially suppressible by low-dose rapamycin, consistent with some other mTORC1 substrates (Figure 2A ) (Kang et al., 2013) . We also tested if, similar to PASK activity ( Figure 1G ), PASK phosphorylation was also induced by constitutively-activated Rheb (Rheb Q64L ) and if that is dependent upon the catalytic activity of PASK. As shown in Figure 2B , both WT and KD (kinase dead) PASK showed enhanced in-cell phosphorylation in the presence of Rheb Q64L . In contrast, the phosphorylation of PDK1, an upstream activator of Akt that is not an mTORC1 substrate, was not induced by Rheb co-expression. Thus, mTORC1 activation induces the phosphorylation of PASK in cells, and the increased PASK phosphorylation is independent of its own catalytic activity, demonstrating that autophosphorylation is not required.
To identify residues on PASK that are specifically targeted by mTORC1 activity, we performed a domain truncation analysis in the presence or absence of Rheb Q64L and rapamycin ( Figure 2C ). Rheb stimulated PASK phosphorylation within both the Cterminal kinase domain-containing region including residues 949-1323 as well as the Nterminal fragment containing the first 749 residues ( Figure 2D) . Surprisingly, these two regions showed differences in sensitivity to rapamycin inhibition as the C fragment showed much more rapamycin sensitivity than the N fragment (see discussion). Using mass spectrometry, bioinformatics, and site-directed mutagenesis, we identified two clusters of sites that were hyperphosphorylated upon mTORC1 activation. The sites within the N-terminal fragment include Ser 640 and Thr 642 ( Figure 2E ). The C-terminal phosphorylation sites include Ser 949 , Ser 953 , and Ser 956 . Mutation to alanine of either cluster alone had minimal effect on PASK phosphorylation induced by Rheb Q64L expression ( Figure 2F ). Mutation of all five sites (S 640 , T 642 , S 949 , S 953 , S 956 to Ala, termed S[5]A) however, resulted in essentially complete inhibition of Rheb-stimulated PASK phosphorylation ( Figure 2F ) and kinase activation ( Figure 2G ). mTORC1 activates multiple kinases within the AGC family of protein kinases, such as Akt, p70S6K, and p90RSK. However, inhibition of these AGC kinases with a pan-AGC kinase inhibitor AT13148 did not affect Rheb-stimulated PASK phosphorylation ( Figure 2H ). Interestingly, the sequence surrounding the Rheb-stimulated PASK phosphorylation sites appears similar to many of the recently identified mTORC1
substrates (Kang et al., 2013) . To test if mTORC1 can directly phosphorylate these sites, we utilized a mutagenized peptide array system to identify novel mTORC1 substrates as previously described (Kang et al., 2013) . The mutated peptide library was generated by mutating phosphorylable residues within each peptide except the phosphorylatable residue at position 0 (indicated by * in Figure 2I ). These peptides were then used as substrates for in vitro kinase reactions with purified mTORC1. As shown in Figure 2J -K, a peptide in which Thr 642 was the only phosphorylatable residue (in Site A sequence) showed similar phosphorylation to the WT peptide. Site B was used as a negative control, being a poor mTORC1 substrate in our experiments. On the other hand, Site C showed robust phosphorylation by mTORC1 and mutation of Ser 949 was sufficient to significantly diminish mTORC1-mediated phosphorylation of this peptide ( Figure 2J -K) in vitro. Taken together, our data suggest that mTORC1-mediated phosphorylation of PASK at multiple residues is required for nutrient and insulin signaling to activate PASK.
PASK forms a nutrient-sensitive complex with mTOR complex 1.
To understand the mechanistic basis whereby PASK is phosphorylated and activated by mTORC1, we sought to understand whether PASK associates with mTOR or any of its associated Complex 1 proteins. We first immunoprecipitated V5-tagged WT PASK or a K1028R mutant lacking kinase activity (KD) from cells that co-express either Myc-tagged WT mTOR or a D2357E/V2364I mutant lacking kinase activity (KD). Both WT and KD PASK could be immunoprecipitated with either the WT or KD version of mTOR ( Figure 3A) . Interestingly, the WT PASK associated with KD mTOR showed significantly diminished phosphorylation at Thr 307 , which is an autophosphorylation site that we have shown previously to be a reliable marker of PASK activity (Wu et al., 2014) .
Thus, KD mTOR appears to function as a dominant negative towards PASK activity.
When endogenous mTOR was isolated from cells, PASK was co-purified in addition to the members of the mTORC1 complex ( Figure 3B ). Similarly, immunoprecipitation of PASK-V5 co-purified endogenous mTOR and raptor ( Figure 3C ). When mTOR was silenced, the association of PASK with mTOR and with Raptor was significantly reduced suggesting that the PASK-Raptor association is likely mediated by mTOR. Using domain truncation analysis, we found that the C-terminal residues 949-1323 in PASK, which include the kinase domain and surrounding regions, are necessary to interact with endogenous mTORC1 ( Figure 3D ). Finally, we found that a mixture of L-leucine and Larginine, as well as expression of Rheb Q64L , two of the stimuli that led to phosphorylation and activation of PASK, both weaken the PASK-mTOR association ( Figure 3E ). Thus, PASK appears to form a nutrient and signaling-sensitive complex with mTORC1, similar to what was previously reported for the mTOR-Raptor association (Kim et al., 2002) .
These data suggest that PASK dynamically associates with mTORC1 wherein mTOR directly phosphorylates and activates PASK, resulting in its release from the complex.
mTORC1 and PASK activate the myogenesis program
Myog expression in myoblasts marks irreversible commitment to differentiate (Olguin et al., 2007) . Hence, activation of Myog transcription is a major focal point of the signaling pathways that regulate myogenesis (Mok and Sweetman, 2011) . As a tissue with significant metabolic demand, skeletal muscle homeostasis is tightly linked with nutrient status. This is consistent with the fact that the nutrient-responsive mTORC1 has been shown to regulate myogenesis and myofiber hypertrophy (Erbay and Chen, 2001; Ge and Chen, 2012; Saxton and Sabatini, 2017; von Maltzahn et al., 2011; Zhang et al., 2015) although its downstream effectors remain unknown (Ge and Chen, 2012) . Because mTORC1 activates PASK and we previously demonstrated that PASK is required for efficient damage-induced myogenesis (Kikani et al., 2016) , we hypothesized that mTORC1-dependent PASK activation is a mechanism whereby nutrient signaling could be coupled to myogenesis. We first compared myogenic induction upon loss of PASK and mTORC1 signaling in both MuSCs and C2C12 myoblasts. As shown in Figure 4A -B, both mTORC1 and PASK inhibition (with rapamycin and BioE-1197, respectively) effectively and similarly suppressed MyoG + conversion and myoblast fusion in isolated MuSCs. This failure to convert to MyoG + cells appears to be due to impaired induction of Myog mRNA in the presence of the inhibitors ( Figure 4C ). We next sought to identify components of the mTORC1 and mTORC2 complexes that are necessary for MyoG expression and myogenesis. To do so, we silenced mTOR, Raptor (member of mTORC1), Rictor (member of mTORC2) or the mTORC1 substrates, p70S6K (major substrate of mTORC1) or PASK during insulin-stimulated myogenesis. Consistent with a previous report (Bentzinger et al., 2008) , mTORC1 but not mTORC2 is required for MyoG protein expression as loss of Raptor but not Rictor suppressed MyoG induction ( Figure 4D ).
Furthermore, silencing of PASK, but not p70S6K, suppressed MyoG expression, suggesting that mTORC1-PASK but not mTORC1-S6K signaling is required for induction of the myogenic program.
Finally, to determine how mTORC1 activation affects myogenesis and what role PASK plays in that process, we silenced Tsc2 in cultured myoblasts and analyzed the mRNA levels for Pax7, Myog, and Acta1 which marks proliferating, committed and differentiated stages, respectively. As shown in Figure 4E , loss of Tsc2 resulted in a modest but significant decrease in Pax7 mRNA and an increase in Myog mRNA, suggesting mTORC1 activation increases myogenic commitment. This is further evidenced by increased expression of the muscle-specific actin Acta, which marks terminally differentiated myocytes. This effect of mTORC1 hyperactivation on increased commitment and myogenesis was completely suppressed by either inhibition of PASK or mTORC1. These data suggest that mTORC1 and PASK are both required for myogenin expression during myogenesis and that PASK might be a novel mTORC1 substrate and effector in this process. 
PASK is a downstream target of mTORC1 to stimulate myogenic initiation
MuSCs from
PASK phosphorylation of Wdr5 is required for mTORC1-stimulated myogenesis
We have previously shown that phosphorylation of Wdr5 is necessary and sufficient for the effects of PASK to induce Myog transcription and myogenesis (Kikani et al., 2016) . Moreover, the physical interaction between PASK and Wdr5 was specifically induced upon insulin treatment to initiate myogenesis (Kikani et al., 2016) . Herein, we showed that insulin treatment also stimulated PASK phosphorylation and activation in an mTORC1-dependent manner. Hence, we hypothesized that mTORC1 activation might enhance the PASK-Wdr5 association. To test this, we co-expressed WT or KD PASK with WT Wdr5 in the presence or absence of Rheb Q64L and measured the PASK-Wdr5 association. As expected, expression of Rheb Q64L caused increased PASK activity as measured by autophosphorylation at Thr 307 ( Figure 6A ). This was coincident with augmentation of the PASK-Wdr5 interaction. Interestingly, the C-terminal residues where mTORC1 phosphorylates PASK are adjacent to the Wdr5 binding region in PASK that we identified previously (Kikani et al., 2016) (Figure 6B ). To more precisely map the Wdr5 binding region in PASK, we mutagenized the conserved residues within this stretch and examined effects on the interaction with Wdr5 ( Figure 6C ). As shown in Figure 6D , mutation of the highly conserved C 924 and W 926 PASK residues to alanine resulted in a significantly weakened interaction with Wdr5. As these residues are adjacent to the mTORC1 phosphorylation site on PASK ( Figure 6C ), we hypothesized that mTORC1-mediated PASK phosphorylation might augment Wdr5 binding. Indeed, we found that the S[5]A mutant, lacking mTORC1-mediated phosphorylation, failed to show Rheb Q64L -dependent induction of the PASK-Wdr5 interaction ( Figure 6E ). Taken together, these data suggest that mTORC1-mediated phosphorylation of PASK stimulates the PASK-Wdr5 association. We have shown previously that this interaction correlates strongly with PASK phosphorylation of Wdr5 at Ser 49 , which orchestrates epigenetic changes at the Myog promoter to enable gene expression. To test if Wdr5 phosphorylation at Ser 49 by PASK is a mechanism whereby mTORC1 signals to induce myogenesis, we first tested whether expression of the phospho-mimetic Wdr5 mutant (Wdr5 S49E ) might rescue the defect in myogenesis resulting from mTORC1 inhibition. As shown in Figure 6F , rapamycin completely prevented the induction of Myog and Mylff in response to differentiation cues. These defects were completely reversed by expression of the phospho-mimetic Wdr5 mutant Wdr5 S49E , while expression of Wdr5 WT or Wdr5 S49A had no effect ( Figure 6F ). Consistent with the mRNA data, western blot analysis showed that Wdr5 S49E , but not Wdr5 S49A also restored MyoG and MHC protein induction in rapamycin-treated cells ( Figure 6G ). Finally, expression of Wdr5 S49E , but not Wdr5 WT (Kikani et al., 2016) . mTORC1 activation of p70S6K simultaneously activates the protein synthesis that is required for rapid myotube hypertrophy, resulting in the culmination of the myogenesis program. Thus, mTORC1 coordinately enables both aspects of myogenesis via activation of distinct protein kinase signaling pathways. mTORC1, PASK, and Wdr5 are widely expressed in stem cells. As PASK is required for differentiation of multiple stem cell lineages (Kikani et al., 2016) , this model could represent a common mechanism by which nutrient and hormonal signaling could establish the commitment to differentiate via mTORC1 signaling. This might be particularly relevant for cell types that are highly metabolically active, like muscle cells and adipocytes (Martin et al., 2015) .
The role of the mTOR protein kinase in the regulation of myogenesis appears to be multi-dimensional (Ge and Chen, 2012) . mTOR has been shown to regulate the myogenesis program using two different mechanisms, only one of which depends upon its catalytic activity (Erbay and Chen, 2001; Ge and Chen, 2012) . Moreover, mTOR regulates not only the early stages of myogenesis but also controls the remodeling of myotubes after differentiation (Risson et al., 2009; Zhang et al., 2015) . Despite considerable interest, it remains unclear how mTOR signals to establish early steps of myogenic commitment in muscle stem cells. Multiple genetic studies and our data in Figure 4E suggest the requirement of the Raptor-containing mTOR complex 1 (mTORC1), but not the Rictor-containing mTORC2 to mediate the early steps of myogenic commitment (Bentzinger et al., 2008; Hung et al., 2014; Rodgers et al., 2014; Wan et al., 2006; Wu et al., 2015) . One of the major substrates of mTORC1, p70S6K1 is dispensable for the early steps of the myogenesis program ( Figure 4E and ( PASK expression was induced several-fold during regenerative myogenesis as early as day 3 post-injury. We and others have observed that this increase in PASK expression originates from proliferating MuSCs (Kikani et al., 2016; Liu et al., 2013) and is coincident with the induction of Myog expression (Rodgers et al., 2014) . Our data presented here suggest that mTORC1-mediated post-translational activation of PASK might provide another layer of control over the critical decision of commitment to differentiate. We propose that such precise signaling control of the epigenetic network is required to regulate myogenesis in accordance with the environmental status. As such, multiple pharmacological and genetic approaches have established that hyper-activation of PI3K/mTORC1 signaling leads to MuSC exhaustion and exacerbates age-associated muscle wasting, presumably due to premature myogenesis and loss of self-renewal potential. Similarly, we show that over-expression of WT PASK ( Figure 5A 
Materials and Methods
Generation of PASK transgenic mice
PASK tagged with V5 at the C-terminus was subcloned into the pBigT plasmid (a kind gift from Mario Capecchi) using the NheI and NotI sites (forward primer 5-CTCACAGCTAGCGCCGCCACCATGGAGGACGGGGGCTTAACAGCC-3, reverse primer 5-GGAAGCGGCCGCTCACGTAGAATCGAGACCGAGGAG-3). This generated a plasmid with V5-PASK downstream of loxP-STOP-loxP. The resulting construct was digested with PacI and AscI and the fragment was inserted into the pROSA-1PA plasmid (a kind gift from Mario Capecchi). The final construct was linearized with SalI and the digestion product was purified by phenol-chloroform extraction. Electroporation of C57Bl/6 ES cells and selection of ES clones was performed by the Transgenic and Gene Targeting Mouse Core at the University of Utah. ES cells were screened for successful targeting of V5-PASK by PCR (forward primer 5-CCTAAAGAAGAGGCTGTGCTTTGG-3, reverse primer 5CATCAAGGAAACCCTGGACTACTG), and by infecting cells with MSCV-Cre (a kind gift from Don Ayer), and analyzing cell lysates by Western blotting with anti-V5 and anti-PASK antibodies. Two correctly targeted clones were injected into blastocysts and generated germline chimeric mice. Genotyping was performed by PCR using DNA isolated from ear biopsies. Primer 1 (5-GGAGGGGAGTGTTGCAATACCTTT-3 and primer 2 (5-AGCTGGGGCTCGATCCTCTAGTTG-3) were used to detect wild-type and transgenic alleles respectively. The PCR program consisted of 2 min at 95C, then 30 cycles of 30 s at 95C, 30 s at 58.5C, 1 min at 72C and 5 min at 72C. Mice were maintained on a C57Bl/6 background. ROSA26 PASK.FLS/+ mice were crossed to C57Bl/6 transgenic mice expressing Cre recombinase under a CMV promoter (a kind gift from the Transgenic and Gene Targeting Mouse Core at the University of Utah) to generate experimental animals (ROSA26 hPASK-V5 ).
Cell lines
HEK293E, HEK293T, and C2C12 myoblasts were obtained from ATCC. Parental Tsc2 -/-and hTsc2-complemented MEFs were a gift from Dr. Brendan Manning. These cells were all cultured in DMEM supplemented with 10% Fetal Bovine Serum and 1% Penicillin and Streptomycin. For amino acid stimulation, custom DMEM was ordered from Invitrogen to lack L-leucine or L-leucine and L-arginine. For all nutrient and insulin stimulation experiments, either C2C12, HEK293E or MEFs were used as these cells respond to insulin. HEK293T cells were used for an experiment involving Rheb Q64L overexpression. All cells were routinely checked for the presence of mycoplasma and were karyotyped by ATCC.
All cells were kept at 37°C with 5% CO2.
Isolation of primary myoblasts
MuSCs were isolated from 10-12 week old WT and PASK -/-littermates according to published protocols (Danoviz and Yablonka-Reuveni, 2012) . Briefly TA muscles from hind-limbs of WT or PASK -/-mice were isolated, minced in DMEM and enzymatically digested with 0.1% Pronase for 1 hr. After repeated trituration, the cell suspension was filtered through a 40 μM filter. Cells were plated on Matrigel-precoated plates and allowed to grow for four days. The differentiation of these MuSC-derived myoblasts was stimulated by the addition of 100 nM insulin in serum-free DMEM.
Insulin, amino acids and glucose stimulation
For insulin stimulation to measure PASK activity using HEK293E or MEFs, cells were serum-starved overnight (12 hr) in DMEM without FBS. Inhibitors such as rapamycin were also added during serum starvation as indicated. 100nM insulin or vehicle control was added directly to the culture media. Cells were incubated at 37°C for the times indicated in each experiment. For amino acid stimulation, cells were serum and amino acids starved overnight. Following, a freshly prepared solution of L-leucine was added directly to the culture medium at a 0.8mM final concentration. Similarly, for glucose stimulation, cells were cultured overnight in low glucose media (1g/L) followed by glucose free DMEM for 1hr. Cells were then stimulated with a final concentration of 25mM D-glucose.
Cell lysis and immunoprecipitation
For immunoprecipitations, cells were lysed in a native lysis buffer containing 40mM HEPES pH 7.4, 150mM NaCl, 2mM KCl, 1mM EDTA, 1mM EGTA, 100mM Sodium pyrophosphate, 10mM β-glycerophosphate and protease and phosphatase inhibitor cocktails. Lysates were incubated on ice for 15 min followed by high-speed centrifugation to pellet insoluble debris. The soluble fraction was subjected to immunoprecipitation using the antibodies as indicated.
In vitro kinase assay
The in vitro kinase assays were performed essentially as described previously (Kikani et al., 2010; Kikani et al., 2016) . Briefly, endogenous or over-expressed PASK was purified from cells using anti-PASK antibody or anti-V5 antibody using native cell lysis buffer as described above. The kinase reaction was performed by washing immunoprecipitated PASK with Kinase buffer without ATP (20mM HEPES 7.4, 10mM MgCl2, 50μM ATP, 1mM DTT). The kinase reaction was initiated by adding 100ng of purified Wdr5 or Ugp1 as substrate and 1 μCi/reaction of [γ-32 P]ATP (PerkinElmer Life Sciences). The reaction was terminated after 10 min by adding denaturing SDS sample buffer. The proteins were separated by SDS-PAGE, transferred to a nitrocellulose membrane and visualized by autoradiography. Western blot analysis using anti-PASK or anti-V5 antibody was performed on the same membrane to determine loading for normalization purposes.
Metabolic in vivo labeling
Metabolic in vivo labeling was performed in cells expressing various PASK plasmids with or without constitutively active Rheb (Rheb Q64L ). 24 h after transfection, cells were washed twice with phosphate-free DMEM (Invitrogen) followed by incubation with 1.0 mCi of 32 P. Cells were washed with phosphate-free DMEM to remove unincorporated 32 P, lysed using lysis buffer, and immunoprecipitated as described above. Immunocomplexes were washed with buffer (20 mM Na2HPO4, 0.5% Triton X-100, 0.1% SDS, 0.02% NaN3) containing high salt (1M NaCl and 0.1% BSA) followed by low salt (150 mm NaCl) in the same buffer. Immuno-precipitated PASK was released by SDS-PAGE sample loading buffer, separated by SDS-PAGE, followed by transfer to nitrocellulose membrane and autoradiographic imaging. HEK293E cells were starved of amino acids and glucose for 8 hr, followed by stimulation with either 25 mM glucose or 800 M L-leucine for 1 hr. Endogenous PASK was purified using anti-PASK antibody from cell extracts and in vitro kinase activity was performed as in [A] .
Immunofluorescence microscopy
Primary myoblasts isolated from
[D] PASK from HEK293E cells was assayed as in [C] . Cells were stimulated with 100nM insulin for 1 hr after pretreatment with DMSO, 100nM Rapamycin or 25μM AICAR for 4 hr. Endogenous PASK was purified using anti-PASK antibody from cell extracts and in vitro kinase activity assay was performed as in [A] .
[E] Quantification of [D] . Phospho-PASK ( 32 P-PASK) and total PASK were quantified from three independent experiments and the ratio expressed as the fold change in PASK activity under the indicated stimuli. Error bars are ± S.D. *P<0.05, **P<0.
[F] V5-PASK was expressed in
Tsc2 -/-cells with or without complementation with wild-type hTsc2. Cells were serumstarved overnight and then stimulated with 100nM insulin for 1hr. PASK was immunoprecipitated using anti-V5 antibody and in vitro kinase assay was performed.
The yeast Ugp1protein, which is a robust in vitro substrate of PASK, was used as an exogenous substrate.
[G] PASK was purified from HEK293T cells with a vector control (-2 ) or expressing Rheb Q64L and was purified and subjected to kinase activity assay as in [F] .
[H] HEK293E cells were transfected with control or mTOR-targeting siRNA for 24 hr. A vector expressing V5-PASK was then transfected and, after 24 hr, cells were serumstarved overnight and then stimulated with 100nM insulin for 1 hr. PASK was purified and subjected to kinase activity assay as in [F].
[I] MuSCs isolated from Rosa26 hPASK-V5 mice were transfected with control or mouse Tsc2-targeting siRNA. 24 hr after transfection, cells were switched to 5% serum-containing medium overnight followed by 4 hr of total serum starvation. Cells were then treated with vehicle or 100nM insulin for 1 hr. PASK was then purified and subjected to kinase activity assay as in Phosphorylation of peptide by mTORC1 as analyzed by dot-blot as described in methods. 
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Site ( [A] Vector control or WT or KD (K1028R) PASK was co-expressed with either Myc-tagged WT or D2357E (KD) mTOR in HEK293T cells. 24 hr after transfection, V5-tagged proteins were purified, and the presence of Myc-tagged mTOR was detected by western blotting.
Immunoprecipitates were also probed with anti-AKT substrate antibody as described in methods to detect PASK-T307 phosphorylation.
[B] mTOR protein was purified from HEK293T cells and the presence of its associated proteins was detected in the immunoprecipitates by western blotting.
[C] mTOR silencing and V5-hPASK expression and immunoprecipitation were performed as described in Figure 1H 
